The independent medical news service

The clinical cell-cycle risk score is able to accurately predict metastasis risk in men undergoing dose-escalated radiation therapy, with or without androgen deprivation therapy, for intermediate- to high-risk localized prostate cancer, research suggests.

Dose intensification does not improve the outcomes of salvage radiotherapy after radical prostatectomy, the SAKK 09/10 investigators have reported at the 2021 Genitourinary Cancers Symposium.

The radiolabeled small molecule lutetium-177-prostate-specific membrane antigen-617 offers higher activity and better patient-reported outcomes than cabazitaxel in metastatic castration-resistant prostate cancer, research shows.

Combining a PD-1 inhibitor with docetaxel could benefit chemotherapy-naïve men with metastatic castration-resistant prostate cancer, suggest results from two early-phase trials.

The total number of radiotherapy courses delivered in England fell significantly during the first peak of the COVID-19 pandemic but this was accompanied by a rapid increase in the use of hypofractionated regimens, study data show.

Further analysis of patients with nonmetastatic castration-resistant prostate cancer from the SPARTAN trial has identified molecular biomarkers associated with long-term responses to apalutamide.